NAARDEN, The Netherlands, May 18, 2021 / B3C newswire / -- Forbion, a leading European life sciences venture capital firm, is pleased to announce that Jasper Bos, PhD, a former Merck executive, has joined its growing investment team as General Partner for the firm’s Growth Fund. Before joining Forbion’s Naarden-based headquarters, Jasper was Senior Vice President and Managing Director at M Ventures, the venture arm of pharmaceutical giant Merck, which he joined in 2009. At M Ventures, he led a team of twenty-one investment professionals and with a fund size of €400 million invested in over 50 portfolio companies spanning biotech, life sciences tools, and tech companies with investment activities ranging from seed-stage to cross-over and IPO.
“In light of the recent, sizable final close, at the EUR 360 million hard cap of our Forbion Growth Opportunities Fund I, we are pleased to have a seasoned life sciences investment professional like Jasper joining our growing team. Jasper has overseen four companies through their IPO process, and has vast experience with pharma spin-outs and prominent licensing deals involving diverse stakeholders from big-pharma to leading academic institutions. His scientific and financial experience will be instrumental as we continue implementing our strategy which is to enable the most innovative companies bring new impactful treatments and therapies to market,” explained Sander Slootweg, Managing Partner at Forbion.
Commenting on his appointment as General Partner Jasper Bos added, “I am excited to be joining Forbion, in my view one of the leading investment firms in the life sciences space, and to actively contribute to deploying their Growth Opportunities Fund and thus help to grow the market for late-stage European biotech investing in Europe. I look forward to working with the Forbion team, and I am confident that my track record in the industry will be complementary to theirs, especially when it comes to creating pharma spin outs.”
Previously, Jasper has worked at the Netherlands Vaccine Institute, the Dutch National Institute of Public Health and in private equity. He holds a PhD in Pharmacy from the University of Groningen, the Netherlands.
Forbion is a dedicated life sciences venture capital firm with offices in The Netherlands, Germany and Singapore. Forbion invests in life sciences companies that are active in the (bio) pharmaceutical space.
Forbion manages well over EUR 1.7 billion across multiple fund strategies that cover all stages of (bio)pharmaceutical drug development. Forbion’s current team consists of 20 life sciences investment professionals that have built an impressive performance track record since the late nineties with successful investments in over 69 companies.
The firm is a signatory to the United Nations Principles for Responsible Investment. Besides financial objectives, Forbion selects investments that will positively affect the health and well-being of patients.
Its investors include the EIF, through its European Recovery Programme (ERP), LfA, Dutch Venture Initiative (DVI), AMUF and EFSI facilities and KfW Capital through the Programme, “ERP – Venture Capital Fonds investments”. Forbion operates a joint venture with BGV, the manager of seed and early-stage funds, especially focused on Benelux and Germany.
Sander Slootweg, Managing Partner
+31 (0) 35 699 30 00
Laura Asbjornsen, Head of Communications
+31 (0) 35 699 32 21
Instinctif Partners for Forbion
Melanie Toyne-Sewell / Agnes Stephens / Phil Marriage
+44 (0)207 457 2020
Keywords: Investments; Financial Management; Capital Financing; Biological Science Disciplines; Biotechnology; Commerce; Europe; Netherlands; Germany; Singapore
Published by B3C newswire